Results 171 to 180 of about 8,566 (280)

Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy. [PDF]

open access: yesInt J Mol Sci
Grimaldi A   +10 more
europepmc   +1 more source

The Cost of Love: Emotional Labour and Moral Tensions in the Lives of Chinese Young Carers

open access: yesThe British Journal of Sociology, Volume 77, Issue 2, Page 286-299, March 2026.
ABSTRACT Like adults, children also provide care. This article explores the emotional labour of young carers who care for ill or disabled family members in China, a context where children's caregiving remains largely invisible in both policy and scholarship.
Kefan Xue, Kaidong Guo
wiley   +1 more source

Piezo1‐Mediated Mechanotransduction: Orchestrating the Dynamic Response of Podocytes and Parietal Epithelial Cells to Mechanical Stress

open access: yesActa Physiologica, Volume 242, Issue 3, March 2026.
ABSTRACT Aim The glomerulus is a specialized microvascular unit that filters plasma through the coordinated function of podocytes and parietal epithelial cells (PECs). From this perspective, the glomerulus functions like a living hydrogeological filtration system.
Maria Elena Melica   +3 more
wiley   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

open access: yesCancer Science, Volume 117, Issue 3, Page 749-758, March 2026.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada   +9 more
wiley   +1 more source

Karyomegalic interstitial nephritis: A case series and review of the literature on genetic insights and clinical challenges. [PDF]

open access: yesClin Nephrol Case Stud
Ozcan SG   +6 more
europepmc   +1 more source

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study

open access: yesEuropean Journal of Neurology, Volume 33, Issue 3, March 2026.
This prospective cohort study identifies independent predictors of relapse following complete treatment discontinuation in 196 myasthenia gravis (MG) patients who achieved minimal symptom expression (MSE). Cox regression analysis revealed late‐onset MG (age ≥ 50 years) as a risk factor, while rituximab therapy, longer treatment duration, and extended ...
Dingxian He   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy